Literature DB >> 18178692

Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans.

J A Singh1, V Strand.   

Abstract

OBJECTIVE: To better understand the impact of gout on functional status, health-related quality of life (HRQoL), mortality and healthcare utilisation in US veterans.
METHODS: All veterans seen in Veterans Integrated Service Network-13 from 1 October 1996 to 31 March 1998 received mailed surveys asking about demographic characteristics; performance of activities of daily living and HRQoL by Short Form-36 (SF-36) for Veterans. Administrative data included demographics; inpatient/outpatient healthcare utilisation; ICD-9 codes for gout, medical comorbidities and arthritis excluding gout-"arthritic comorbidity" and 1-year mortality. Multivariable estimates compared results between veterans with/without gout using least means squared.
SUBJECTS: with gout were significantly older, retired, not married, current non-smokers, with more comorbidities. Multivariable-adjusted bodily pain was somewhat worse (49.7 vs 47.1, p<0.01) and mental health (66.7 vs 68.6, p<0.01) domain scores somewhat better in patients with gout, both differences significant but not clinically meaningful (less than threshold of 5-10 points); other SF-36 domain and summary scores and functional limitations were similar. Medical or arthritic comorbidities predicted clinically/statistically lower adjusted scores in all SF-36 domains and physical domains (physical component summary), respectively. Patients with gout had significantly more annual primary care visits (3.5 vs 2.7, p<0.001) and admissions to hospital (18.3% vs 15.1%, p<0.01), fewer mental health visits (10.1% vs 13.7%, p<0.01) and similar mortality (2.6% vs 2.2%, p = 0.23).
CONCLUSIONS: Gout is independently associated with higher medical and arthritic comorbidity, primary care and inpatient utilisation. Poorer HRQoL, functional limitation and higher mortality noted in univariate analyses in patients with gout were attributable to higher comorbidity and sociodemographic characteristics.

Entities:  

Mesh:

Year:  2008        PMID: 18178692     DOI: 10.1136/ard.2007.081604

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  95 in total

1.  Quality of care in patients with gout: why is management suboptimal and what can be done about it?

Authors:  N Lawrence Edwards
Journal:  Curr Rheumatol Rep       Date:  2011-04       Impact factor: 4.592

2.  Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.

Authors:  Ted R Mikuls; T Craig Cheetham; Gerald D Levy; Nazia Rashid; Artak Kerimian; Kimberly J Low; Brian W Coburn; David T Redden; Kenneth G Saag; P Jeffrey Foster; Lang Chen; Jeffrey R Curtis
Journal:  Am J Med       Date:  2018-11-29       Impact factor: 4.965

3.  Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.

Authors:  Seoyoung C Kim; Sebastian Schneeweiss; Niteesh Choudhry; Jun Liu; Robert J Glynn; Daniel H Solomon
Journal:  Am J Med       Date:  2015-02-03       Impact factor: 4.965

Review 4.  Risk factors for gout and prevention: a systematic review of the literature.

Authors:  Jasvinder A Singh; Supriya G Reddy; Joseph Kundukulam
Journal:  Curr Opin Rheumatol       Date:  2011-03       Impact factor: 5.006

Review 5.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

6.  Association of incident gout and mortality in dialysis patients.

Authors:  Scott D Cohen; Paul L Kimmel; Robert Neff; Lawrence Agodoa; Kevin C Abbott
Journal:  J Am Soc Nephrol       Date:  2008-05-28       Impact factor: 10.121

7.  [Differential diagnosis and therapy of gout].

Authors:  Monika Reuss-Borst
Journal:  Med Klin (Munich)       Date:  2009-09-15

Review 8.  Quality of life and quality of care for patients with gout.

Authors:  Jasvinder A Singh
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 9.  Gout. Novel therapies for treatment of gout and hyperuricemia.

Authors:  Robert Terkeltaub
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

10.  Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.

Authors:  Angelo L Gaffo; Kenneth G Saag
Journal:  Core Evid       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.